AngioDynamics (ANGO) had its price target lowered by Canaccord Genuity Group Inc. from $18.00 to $16.00. They now have a "buy" rating on the stock.
AngioDynamics Growing, But With More Noise Than The Street Likes [Seeking Alpha]
AngioDynamics Inc (ANGO) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Amid Financial ... [Yahoo! Finance]
AngioDynamics Q3 Earnings Call Highlights [Yahoo! Finance]
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability